{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"A MULTICENTER, OPEN LABEL, RANDOMIZED, PHASE 2 STUDY OF VENETOCLAX AND AZACITIDINE PLUS CUSATUZUMAB VERSUS VENETOCLAX AND AZACITIDINE ALONE IN NEWLY DIAGNOSED AML PATIENTS WHO ARE NOT CANDIDATES FOR INTENSIVE THERAPY","item":"https:\/\/www.regionalcancercare.org\/trials\/a-multicenter-open-label-randomized-phase-2-study-of-venetoclax-and-azacitidine-plus-cusatuzumab-versus-venetoclax-and-azacitidine-alone-in-newly-diagnosed-aml-patients-who-are-not-candidates-for-i\/#breadcrumbitem"}]}